Louis Rodgers
Connect
ltro223@uky.eduCollege Unit(s)
Other Affiliation(s)
- College of Pharmacy
Biography and Education
Learner Information
Why did you choose the University of Kentucky?
1) The students in the program felt like a family.
2) UK treats an extremely diverse set of conditions/diseases, exposing students to highly valuable skills and experiences during their clinical training.
3) UK is among the top research institutions in the country and has incredible resources (Markey Cancer Center, CTSA award, mentors) to pursue my research interests.
What are your hobbies?
Distance running, weightlifting, listening to podcasts while walking my dog Woodford
Education
Ph.D. Pharmaceutical Sciences - UK (2019-2024)
CRTA Postbac - NIH/NCI (2015-2017)
B.S. Chemistry - Centre College (2011-2015)
Summary:
Current Year: M3 B.S. Chemistry - Centre College; PhD Pharmaceutical Sciences - UKY Hometown: Florence, KYResearch
Following his undergraduate education at Centre College, Louis participated in the NIH Postbac CRTA Program under the guidance of Dr. William Figg (clinical pharmacology/genitourinary malignancies) and Dr. Katherine Warren (pediatric neuro-oncology). During his time at the NIH, Louis conducted pharmacokinetic studies in an effort to develop new therapeutic strategies for the treatment of cancers in children with tumors of the central nervous system. With an interest in continuing in the field of neuro-oncology, Louis was thrilled to pursue a career as a physician-scientist at the University of Kentucky because of its strong oncology and neuroscience programs. Louis recently completed his PhD in the laboratory of Dr. Bjoern Bauer, focusing on the inhibition of PI3K/Akt to enhance the brain uptake of anticancer agents for the treatment of glioblastoma.
Selected Publications
Rodgers LT, Maloney BJ, Hartz AMS, Bauer B. Fluorescence-Guided Resection of GL261 Red-FLuc and TRP-mCherry-FLuc Mouse Glioblastoma Tumors. Cancers (Basel). 2025; 17(5):734. (IF: 4.5)
Rodgers LT, Villano JL, Hartz AMS, Bauer B. Glioblastoma Standard of Care: Effects on Tumor Evolution and Reserve Translation in Preclinical Models. Cancers (Basel). 2024; 16(15):2638. (IF: 5.2)
Rodgers LT, Schulz Pauly JA, Maloney BJ, Hartz AMS, Bauer B. Optimization, Characterization, and Comparison of Two Luciferase-Expressing Mouse Glioblastoma Models. Cancers (Basel). 2024; 16(11):1997. (IF: 5.2)
Schulz JA, Rodgers LT, Kryscio RJ, Hartz AMS, Bauer B. Characterization and Comparison of Human Glioblastoma Models. BMC Cancer. 2022 (IF: 4.430)
Lester McCully C, Rodgers LT, Cruz R, Thomas ML, Peer CJ, Figg WD, Barnard D, Warren KE. Cerebrospinal fluid flow rate and apparent volume in rhesus macaques (Macaca mulatta) as determined by the pharmacokinetics of intrathecally administered inulin. Comp Med. 2020. doi: 10.30802/AALAS-CM-99-990010 (IF: 0.800)
Hipp S, Goldman S, Kaushal A, Krauze A, Citrin D, Glod J, Walker K, Shih JH, Sethumadhavan H, O鈥橬eill K, Garvin JH, Glade-Bender J, Karajannis MA, Atlas MP, Rodgers LT, Peer CJ, Savage J, Camphausen KA, Brunson N, Packer R, Streicher H, Figg WD, Warren KE. A Phase I Trial of Lenalidomide and Radiotherapy in Children with Diffuse Intrinsic Pontine Gliomas or High-Grade Gliomas. J Neurooncol. 2020. doi: 10.1007/s11060-020-03627-0 (IF: 3.267)
Vyas KS, DeCoster RC, Burns JC, Rodgers LT, Shrout MA, Mercer JP, Coquillard C, Dugan AJ, Rinker BD, Vasconez HC. Autologous Fat Grafting Does Not Increase Risk of Oncologic Recurrence in the Reconstructed Breast. Ann Plast Surg. 2020. doi: 10.1097/SAP.0000000000002285 (IF: 1.448)
McCully CM, Rodgers LT, Cruz R, Thomas ML, Peer CJ, Figg WD, Warren KE. Plasma and Cerebrospinal Fluid Pharmacokinetics of the DNA methyltransferase inhibitor, 5-azacytidine, Alone and in Combination with Inulin in Non-human Primate CSF Models. Neuro-Oncology Advances. 2020. doi: 10.1093/noajnl/vdaa005
Rodgers LT, McCully CM, Odabas A, Cruz R, Peer CJ, Figg WD, Warren KE. Characterizing the Pharmacokinetics of Panobinostat in a Non-human Primate Model for the Treatment of Diffuse Intrinsic Pontine Glioma. Cancer Chemother Pharmacol. 2020; 85(4): 827-830. doi:10.1007/s00280-019-04021-y (IF: 3.008)
Peer CJ, Jung-Min L, Roth J, Rodgers L, Nguyen J, Annunziata CM, Minasian L, Kohn EC, Figg WD. Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women鈥檚 cancers. Cancer Chemother Pharmacol. 2017; 80(1): 165-175. doi: 10.1007/s00280-017-3346-1 (IF: 2.808)
Rodgers L, Peer CJ, Figg WD. Diagnosis, staging, and risk stratification in prostate cancer: utilizing diagnostic tools to avoid unnecessary therapies and side effects. Cancer Biol Ther. 2017; 18(7): 470-472. doi: 10.1080/15384047.2017.1323600 (IF: 3.373) (Review)
Miyahara H, Yadavilli S, Natsumeda M, Rubens J, Rodgers L, Kambhampati M, Taylor I, Kaur H, Asnaghi L, Eberhart CG, Warren KE, Nazarian J, Raabe EH. The dual mTOR kinase inhibitor TAK 228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma. Cancer Lett. 2017; 400: 110-116. doi: 10.1016/j.canlet.2017.04.019 (IF: 6.491)
League-Pascual JC, McCully CM, Shandilya S, Ronner L, Rodgers L, Cruz R, Peer CJ, Figg WD, Warren KE. Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. J Neurooncol. 2017; 132(3): 401-407. doi: 10.1007/s11060-017-2388-x (IF: 3.060)
Peer CJ, Ronner L, Rodgers L, McCully CM, Warren KE, Figg WD. Quantification of temozolomide in nonhuman primate fluids by isocratic ultra-high performance liquid chromatography-tandem mass spectrometry to study brain tissue penetration following intranasal or intravenous delivery. Separations. 2016; 3(1), 4. doi: 10.3390/chromatography3010004 (IF: 2.690)